Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

FTC Backs Antitrust Scrutiny of Amgen Over Enbrel Patent Deal

21 August 2026 · By · Wire by Fusion42

Published

21 August 2026

Topic

regulatory

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at news.bloomberglaw.com →

◆ Verified

Fusion42 · 21 August 2026 · Fusion42 review

The US Federal Trade Commission supports ongoing antitrust investigation into Amgen's patent settlement involving the drug Enbrel, highlighting regulatory scrutiny on pharmaceutical patent deals that may limit competition.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You face tougher barriers if your biotech relies on extended patent deals to block generics. This scrutiny opens a path for competitors to challenge dominant drug patents more aggressively.

◆ Coverage

1 source · 21 Aug 2026

◆ Related on Wire

◆ Topics

Biotechftcantitrustpharma-patentamgenenbrel